Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.80
  • Today's Change0.52 / 7.14%
  • Shares traded386.08k
  • 1 Year change-83.40%
  • Beta--
Data delayed at least 15 minutes, as of Oct 05 2022 09:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

  • Revenue in HKD (TTM)1.21m
  • Net income in HKD-1.42bn
  • Incorporated2017
  • Employees476.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dawnrays Pharmaceutical Holdings Ltd1.30bn400.02m1.60bn1.06k4.030.58883.441.230.26540.26540.86231.820.38392.397.001,220,386.0011.7211.4513.9513.8359.2658.7130.5329.602.3120.120.010542.6813.757.1733.586.1465.212.29
Jacobson Pharma Corporation Ltd1.60bn177.67m1.68bn1.74k9.380.6694.421.050.09270.09270.83291.300.33162.915.60919,091.603.904.965.376.8838.8941.4111.7613.741.0516.360.322832.4610.354.902.28-0.186-7.1112.02
SinoMab Bioscience Ltd28.54m-349.79m1.85bn283.00--2.96--64.87-0.354-0.3540.02890.62260.0264----100,850.90-32.38---34.63-------1,225.57-----27.170.3432-------135.07------
Essex Bio-Technology Limited1.56bn323.01m1.86bn1.42k5.991.075.181.200.54270.54272.593.040.5751.873.021,128,434.0011.9414.0515.5818.5387.3882.6320.7621.202.0019.460.227215.5767.4316.1258.0320.4847.8724.31
Antengene Corporation Ltd91.11m-624.48m2.16bn329.00--0.8875--23.70-1.00-1.000.14653.660.03072.902.40276,942.40-21.02---22.36--83.94---685.39--11.13-15.730.0156------77.62------
Immunotech Biopharm Ltd0.00-382.47m2.26bn515.00--3.00-----0.7433-0.74330.001.470.00----0.00-33.66---37.53----------1.49-16.450.1291------19.32------
TOT Biopharm International Co Ltd259.06m-178.36m2.30bn337.00--5.11--8.86-0.3101-0.31010.45040.58750.32541.655.17768,737.60-22.41---34.33--73.14---68.85--0.8533-14.000.4296--239.36--9.46------
Abbisko Cayman Ltd-100.00bn-100.00bn2.32bn160.00--0.8473----------3.89----------------------------0.0204-------156.14------
Everest Medicines Ltd1.21m-1.42bn2.62bn476.00--0.4682--2,166.27-4.84-4.840.004118.220.0002--0.09112,986.04-19.03---20.51--64.75---117,819.00--2.36-39.740.0282------82.17------
Clover Biopharmaceuticals Ltd0.00-6.43bn2.63bn814.00--13.49-----12.36-12.360.000.1675------0.00----------------1.29-0.78570.3124-------559.03------
VIVA Biotech Holdings2.41bn122.61m2.65bn2.13k21.260.60618.321.10-0.0098-0.00981.232.260.27237.544.761,132,157.001.492.391.722.6331.0937.435.4710.181.510.94630.416822.00201.9085.23174.3263.68138.39--
Consun Pharmaceutical Group Ltd2.37bn700.78m2.70bn2.77k3.810.88713.431.140.87560.87562.963.770.51472.206.19856,163.1015.2610.9823.9817.7274.5674.4529.6422.722.34--0.135640.3716.6510.8218.3213.9331.4621.69
Acotec Scientific Holdings Ltd373.31m-39.04m2.78bn400.00--2.06--7.45-0.1933-0.19331.364.310.4541.056.38933,278.80-4.75---5.86--84.69---10.46--16.60--0.025--56.62---80.37------
Ascletis Pharma Inc86.51m-194.05m2.90bn266.00--0.9714--33.55-0.1778-0.17780.07932.750.02730.24851.51325,226.20-6.12-4.81-6.30-5.1384.1668.75-224.31-121.0125.63-7.580.0006--119.6418.454.89---30.57--
Jacobio Pharmaceuticals Group Co Ltd165.00m-322.07m3.16bn262.00--1.89--19.12-0.4297-0.42970.222.160.0862--1.44629,766.20-16.83---17.63--11.42---195.19------0.0026---68.58--80.10------
Yichang Hec Changjiang Pharmactcl Co Ltd2.21bn-124.92m3.64bn3.62k--0.572716.191.65-0.142-0.1422.517.230.20331.873.35610,663.60-1.1510.68-1.5914.8767.0282.48-5.6527.100.47470.60630.372738.26-61.08-0.5958-170.00--27.36--
Data as of Oct 05 2022. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

22.44%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 18 Aug 202223.58m7.85%
Janchor Partners Ltd.as of 31 Dec 202017.42m5.80%
Wellington Management Co. LLPas of 21 Mar 202213.88m4.62%
Candriam Belgium SAas of 31 May 20225.47m1.82%
The Vanguard Group, Inc.as of 09 Sep 20222.53m0.84%
BlackRock Fund Advisorsas of 08 Sep 20221.60m0.53%
Wellington Management Singapore Pte Ltd.as of 03 Aug 20211.20m0.40%
Wellington Management Japan Pte Ltd.as of 21 Mar 2022741.50k0.25%
Dimensional Fund Advisors LPas of 31 Aug 2022547.50k0.18%
BlackRock Advisors LLCas of 31 Aug 2022463.50k0.15%
More ▼
Data from 21 Apr 2022 - 15 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.